{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-088061","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2026-08-12T12:04:06+00:00","discovered_at":"2026-08-12T12:05:00.361822+00:00","generated_at":"2026-08-12T12:05:06.258762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Unicycive Q2 net loss narrows to $1.7M; FDA assigns OLC facility inspection","bullets":["Q2 2026 net loss $1.7M ($0.06/sh) vs $6.5M loss ($0.52/sh) in Q2 2025.","Cash, equivalents, and marketable securities $61.4M at June 30, 2026; runway into 2027.","FDA assigned facility inspection to third-party OLC manufacturer; NDA resubmission expected after successful inspection.","June 2026 CRL cited same manufacturing deficiencies as prior CRL; no efficacy or safety concerns.","R&D expense $2.8M (vs $1.8M); G&A $7.4M (vs $5.2M) year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-088061","json":"https://secwatch.observer/filing/0001213900-26-088061.json","markdown":"https://secwatch.observer/filing/0001213900-26-088061.md","text":"https://secwatch.observer/filing/0001213900-26-088061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/0001213900-26-088061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea0301699-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:05:06.258762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}